6971872618 16:36 From: QR Yoodson C. Merrell M Webfax Page: ivii FAX COVER SHEET To: Jeffrey Epstein / Lesley From: Lisa Company;§ ————__ Company: Woodson Merrell MD PLLC Fax: _——k— = Phone: — Date: 9/18/2018 Pages wicover: 11 Subject: 9-14-18 LABCORP (Partial) Lab Re Comments: EFTA00299784

--=PAGE_BREAK=--

6971872618 16:36 From: 3477565616 Woodson C. Merrell M Webfax Page: 2711 ™ r w Specimen ID: 257-480-2371.0 Acct a: 31143092 Phone: te: 68 Control iD: F5831143092 Woodson Merrell EPSTEIN, JEFFREY 44E 67th St 9€ 71ST ST New York NY 10065 NEW YORK NY 10021 tel hee ell Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Agely/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/18/2018 0610 ET NPI: 1023153509 . : General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items CBC With Differential/Platelet; Comp, Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Rfx IFE),S; Lipid Panel; Iron and TIBC; Testosterone, Free+Weakly Sound; Vitamin B12 and Folate; FSH and LH; C-Reactive Protein, Cardiac; Hemoglobin Atc; Prostate-Specific Ag, Serum; TSH; Vitamin D, 25-Hydroxy; Lipoprotein (a); IGF-1; ANA wiReflex; Homocyst(e)ine, Plasma; Prolactin; Thyroxine (T4) Free, Direct, S; Cortisol; DHEA-Sulfate; Estradiol; Uric Acid; Phosphorus; LDH; GGT; Amylase; Ferritin, Serum; insulin; Calcium, lonized, Serum; Fibrinogen Activity; Magnesium, RBC TESTS CBC With Differential/Platelet WBC 5.7 Xx10E3/uL 3.4 - 10.8 o1 RBC 4.90 x1056/uL 4.14 - 5.80 01 Hemoglobin 14.7 g/d 13.0 - 17,7 01 Hematocrit 42.2 $ 37.5 - 51.0 01 MCV 86 £L 79 - 97 01 MCH 30.0 pg 26.6 - 33.0 01 MCHC 34.8 g/dL 31.5 - 35.7 01 RDW 14.6 % 12.3 - 15.4 ol Platelets 242 *10E3/uL 150 - 379 o1 Neutrophils 50 % Not Estab. 01 Lymphe 37 % Not Estab. o1 Monocytes 5 $ Not Estab 01 Eos 7 $ Not Estab. 01 Basos 1 % Not Estab, 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1 x10E3/uL 0.7 - 3.1 o1 Monocytes (Absolute) 0.3 *10E3/uL 0.1 - 0.9 01 Eos (Absolute) 0.4 x10E3/uL 0.0 - 0.4 01 Baso (Absolute) 0.0 *10E3/uL 0.0 - 0.2 01 Immature Granulocytes ts) $ Not Estab. o1 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 01 Comp. Metabolic Panel (14) Glucose 128 High mg/dL 65 - 99 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Date issued: 09/18/18 1053 ET PRELIMINARY REPORT Page 1 ofS This document contains private and confidential nf - tected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in error, please call’ All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299785

--=PAGE_BREAK=--

6971872618 16:38 Fron: i Y“oodson C. Merrell M Vebfax Page: 3/711 Patient: EPSTEIN, JEFFREY DOB: 01/20/1953 Patient ID: Control ID: F5831143692 BUN Creatinine eGFR If NonAfricn Am eGFR If Africn Am BUN/Creatinine Ratio Sodium Potassium Specimen ID: 257-480-2371-0 Date collected: 09/14/2018 1255 Local UNITS RESULT REFERENCE INTERV. 22 ma/dL 8 - 27 01 0.96 mg/dL, 0.76 - 1.27 o1 83 mL/min/1.73 >59 95 mL/min/1.73 >59 23 10 - 24 138 mmol/L 134 - 144 01 4.2 mmol/L 3.5 - 5.2 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. AST, ALT, Chloride Carbon Dioxide, Total Calcium Protein, Total Albumin Globulin, Total A/G Ratio Bilirubin, Total Alkaline Phosphatase AST (SGOT) The specimen was lipemic. ultracentrifugation before testing. cholesterol and triglyceride (if ordered) ultracentrifugation. ALT (SGPT) Urinalysis, Routine Urinalysis Gross Exam Specific Gravity pH Urine-Color Appearance WBC Esterase Protein Glucose Ketones Occult Blood Bilirubin Urobilinogen, Semi-Qn Nitrite, Urine Microscopic Examination 102 20 orPN BHO orw > 3 71 26 mmol/L 96 - 106 01 mmol/L 20 - 29 o1 mg/dL 8.6 - 10.2 01 g/aL 6.0 - 8.5 o1 g/dl 3.6 - 4.8 o1 g/dL 1.5 - 4.5 1.2 - 2.2 mg/dL 0.0 - 1.2 01 Iu/L 39 - 117 o1 Iu/L o - 40 ol The lipemia was cleared by 37 1.027 s.5 Yellow Clear Negative Negative Negative Negative Negative Negative 0.2 Negative Microscopic follows if indicated. PE+Interp(REx IFE),S Will Follow Date issued: 09/18/18 1053 ET PRELIMINARY REPORT This document contains private and confidential i i rotected by state and federel lew. if you have received this document in error, please call However HDL, direct LDL, were performed prior to Tu/ 0 - 44 01 ol 1.005 - 1.030 o1 5.0 - 7.5 01 Yellow 01 Clear 01 Negative o1 Negative/Trace 01 Negative 01 Negative 01 Negative o1 Negative o1 EU/dL 0.2 + 1.0 o1 Negative o1 01 Page 2 of 5 © 1995-2018 Laboratory Corporation of America® Hokfings All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299786

--=PAGE_BREAK=--

6971872618 16:36 Fron: Ee Yoodson C. Merrell M Webfax Page: 4711 LabCorp Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 DOB: 01/20/1953 Patient ID: Control 1D: F5B3 1143092 Date collected: 09/14/2018 1255 Local Lipid Panel Cholesterol, Total 234 High mg/dL 100 - 199 01 Triglycerides 1714 Alert mg/dL O ~ 149 ol Results confirmed on dilution. HDL Cholesterol 19 Low mg/dL >39 01 VLDL Cholesterol Cal mg/dL 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Calc mg/dL Oo - 93 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap. (TIBC) 320 ug/daL 250 ~- 450 vrIBC 252 ug/dL 111 - 343 OL Iron 68 ug/dL 38 - 169 o1 Tron Saturation 21 % 15 - 55 Testosterone, Free+Weakly Bound Testosterone, Serum 140 Low ng/dL 264 - 916 01 Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. Testost., % Free+Weakly Bound Will Follow % 9.0 - 46.0 02 Testost., F+W Bound Will Follow ng/dL 40.0 - 250.0 Vitamin B12 and Folate Will Follow FSH and LH LH 3.7 mIU/mL 1.7 - 8.6 01 FSH 4.4 mIU/mL 1.5 - 12.4 01 C-Reactive Protein, Cardiac 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc Hemoglobin Alc 5.5 $ 4.8 - 5.6 01 Please Note: 01 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 o1 Date Issued: 09/18/18 1053 ET PRELIMINARY REPORT Page 3 of 5 This document contains private and confidential health j is tected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in error, please call’ All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299787

--=PAGE_BREAK=--

6971872618 16:36 From: gigietiettts Woodson C. Merrell M Vebfax Page: 5Sv7ii LabCorp Patient Report Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 BOB: 01/20/1953 Patient ID: Control ID: F5331143092 Date collected: 09/14/2018 1255 Locai RESULT Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.296 ulU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 o1 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine), 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Lipoprotein (a) 20 nmol/L <75 01 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. IGF-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 02 ANA w/Reflex ANA Direct Negative Negative o1 Homocyst(e)ine, Plasma 14.9 umol/L 0.0 - 15.0 01 Prolactin 3.9 Low ng/mL 4.0 - 15.2 01 Thyroxine (T4) Free, Direct, $s T4, Free (Direct) 1.05 ng/dL 0.82 - 1.77 o1 Cortisol 3.7 ug/dbL OL Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 Date Issued: 09/18/18 1053 ET PRELIMINARY REPORT Page 4 of 5 This document contains private and confidential health information protected by state and federal law. © 1995-2018 Laboratory Corporation of Amverica® Holdings if you have received this document in error, please call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299788

--=PAGE_BREAK=--

69718726818 16:38 From: iis Voodson C. Merrell M Webfax Page: 6/711 Lal orp rey Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 DOB: 01/20/1953 Patient iD: Control (D: F5B31143092 Date collected: 09/14/2018 1255 Local UNITS REFERENCE INTE DHEA-Sulfate 181.8 ug/dL 30.9 - 295.6 01 Estradiol 28.3 po/mL 7.6 - 42.6 01 Roche ECLIA methodclogy Uric Acid Uric Acid 6.8 mg/dL 3.7 - 8.6 01 Please Note: o1 Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 01 LDE 213 Iu/L 121 - 224 01 GGT 25 Iu/L 0 - 65 01 Amylase 37 U/L 31 - 124 o1 Ferritin, Serum Will Follow Insulin 47.2 High ulU/mL 2.6 - 24.9 o1 Calcium, Ionized, Serum §.3 mg/dL 4.5 - 5.6 o1 Fibrinogen Activity 330 mg/dL 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution. Magnesium, RBC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease REC Magnesium levels. “OT RN LabCorp Raritan Dir: Araceli B Reyes, MD 69 First Avenue, Raritan, NJ 08869-1800 02 BN LabCorp Burlington Dir: Willam F Hancock, MD 1447 York Court, Burlington, NC 27215-3361 _ For inquiries, the physician may contact Branch: 800-631-5250 Lab: LL TSE Se SS SL RS RS A Date Issued: 09/18/18 1053 ET PRELIMINARY REPORT Page 5 of 5 This document contains private and confidential health information protected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings if you have received this document in error, please le All Rigivts Reserved - Enterprise Report Version: 1.00 EFTA00299789

--=PAGE_BREAK=--

6971872618 16:36 From: giggiiietietetete Woodson C. Merrell M Webfax Page: 7711 LabCorp Tg Specimen ID; 257-480-2232-0 Acct #: 31143092 Phone: Rte: 66 Control iD: F5A31143092 Woodson Merrell EPSTEIN, JEFFREY 44 E 67th St New York NY 10065 pte! hee be hh Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: Agely/rn/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Dateentered: 09/15/2018 ID: MERRELL Patient 1D; Date reported: 09/16/2018 0808 ET ; NPI: . General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Ca+PTH Intact UNITS a4 ERVAL LAB Ca+PTH Intact Calcium 9.5 mg/dL 8.6 - 10.2 01 Specimen received hemolyzed. Clinical correlation indicated. PTH, Intact 71 High pg/mL 15 = 65 01 Intact PTH o1 Interpretation Intact PTH Calcium (pg/mL) (mg/dL) Normal 15 - 65 8.6 - 10.2 Primary Hyperparathyroidism >65 >10.2 Secondary Hyperparathyroidism >65 <10.2 Non-Parathyroid Hypercalcemia <65 >10.2 Hypoparathyroidism <15 < 8.6 Non-Parathyroid Hypocalcemia 15 - 65 < 8.6 [ 01 RN LabCorp Raritan Dir: Araceli B Reyes, MD —_ | _ 69 First Avenue, Raritan, NJ 08869-1800 a For inquiries, the physician may contact ct Branch: i ob: . ” SET 8 ee RES A oe TR EMO A ETAT TN A A AR A TY AE Date Issued: 09/17/18 0916 ET FINAL REPORT Page tof} This document contains private and confidential healt! tected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings IF you have received this document in error, plesse call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299790

--=PAGE_BREAK=--

6971872618 16:38 Fron: mies Woodson C. Merrell M WVebfax Specimen 1D: 257-490-2715-0 Control ID: END31143092 EPSTEIN, JEFFREY 9E7ISTST NEW YORK NY 10021 Patient Details DOB: 01/20/1953 Age(y/m/d): 065/07/25 Gender: M SSN: Patient ID: General Comments & Additional Information Total Volume: Not Provided Specimen Details Ordered Items Chlamycia/GC Amplification; Panel 083935; HCV Ab w/Rflx to Verification; RPR, Rfx Qn RPR/Confirm TP RESULT Chlamydia/GC Amplification Chlamydia trachomatis, NAA Negative Neisseria gonorrhoeae, NAA Negative Panel 083935 HIV Screen 4th Generation wRfx Non Reactive HCV Ab w/Rflx to Verification HCV Ab <O.1 Comment : Date collected: 09/14/2018 1255 Local Date received: 09/15/2018 Date entered: 09/15/2018 ID: Date reported: 09/18/2018 0610 ET Acct #: 31143092 Rte: 68 rhone: aaa Woodson Merrell 44 E 67th St New York NY 10065 el eee el Physician Details Ordering: W MERRELL Referring: NPI: 1023153509 Fasting: No UNITS REFERENCE INTERVAL LAB Negative 01 Negative 01 Non Reactive 01 s/co ratio 0.0 - 0.9 o1 o1 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. RPR, Rfx Qn RPR/Confirm TP RPR Non Reactive Non Reactive 61 oF RN LabCorp Raritan a 69 First Avenue, Raritan, NJ 08! For inquiries, the physician may contact Branch: Dir: Araceli B Reyes, MD __] eT A LE A RR AP? RS SSR Date Issued 05/18/18 1053 ET FINAL REPORT Page lof! This document contains private and confidential health information poscne by state and federal law. if you have received this document in error, please call © 1995-2018 Laboratory Corporation of America® Holdings All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299791 Page: 8711

--=PAGE_BREAK=--

0971872818 16:38 Fron: i Yoodson C. Merrell M Webfax Page: 9711 : LabCorp aaa eos Specimen ID: 257-480-2542. Acct #: 31143092 Phone: MME Rte: 68 Control iD: F5C31143092 EE LT ES ES Woodson Merrell EPSTEIN, JEFFREY 44E 67th St 9E7ISTST New York NY 10065 NEW YORKNY 10021 ete eee etal Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 1D: MERRELL Patient ID: Date reported: 09/15/2018 0823 ET NPI; 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Zinc, Whole Blood UNITS REFER Whole Blood 749 ug/dL 6 01 Zinc, ~~ Dir: William F Hancock, MD ~ 01 BN LabCorp Burlington — 1447 York Court, Burlington, NC 27215-3361 For inquiries, the physician may contact Branch: ty Lab: ty Date Issued 09/18/18 1053 ET FINAL REPORT Page lof 1 This document contains private and confidential health information protected by state and federal taw. © 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in errer, please i All Rights Reserved - Enterprise Report Version: 1,00 EFTA00299792

--=PAGE_BREAK=--

6971872618 16:36 fro: ie Woodson C. Merrell M Webfax Page: 18711 LabCorp ry Specimen ID: 257-480-2300-0 Acct #: 31143092 Phone: Rte: 68 Control iD: 25648023000 Woodson Merrell EPSTEIN, JEFFREY 44 E 67th St 9 EAST 71 STREET New York NY 10065 NYC NY 10021 tie eh ee ell Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/17/2018 2010 ET NPI; 1023153509 _ Ordered Items Heavy Metals Profile ll, Blood Heavy Metals Profile II, Blood Lead, Blood Will Follow ug/dL o-4 01 Blood Lead Collection Method: Venous Testing performed by Inductively coupled plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 BEI 30 Detection Limit = 1 Arsenic, Blood 8 ug/L 2 - 23 o1 Detection Limit = 1 Mercury, Blood 2.1 ug/L 0.0 - 14.9 01 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit = 1,0 Cadmium, Blood None Detected ug/L 0.0 - 1.2 01 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit = 0.5 ot BN LabCorp Burlington Dir: William F Hancock, MD ~ ___1447 York Court, Burlington, NC 27215-3361 _ - For inquiries, the physician may contact Bronch: SEE can: TT tt Date issued: 09/18/18 1053 ET PRELIMINARY REPORT Page 1 of 1 This document contains privete and confidential health information ted by state and federal lave, © 1995-2018 Laboratory Corporation of America® Holdings Hf you have received this document in error, please wi All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299793

--=PAGE_BREAK=--

Woodson C. Merrell M Webfax Page: 11711 tr 781426649025 00/17/2018 21.32 9442 GHB oo, 6971872618 16:38 From: Fromimugen \/IM UGEN’ Reference Diagnostic Division eee Gone Ses Cm te Oxford Immunotec, inc. d/b/a IMUGEN 315 Norwood Park South, Norwood MA 02062 « QIN « FX Lyme Antibody Analysis Submitter: Patient: WOODSON C MERRELL MD Name: JEFFREY EPSTEIN SUITE 1B Address: 9 EAST 71ST STREET 44 EAST 67TH STREET NEW YORK, NY 10021 NEW YORK, NY 10065 0.0.8: 01/20/1953 Ordering Submitter Provider; © WOODSON C MERRELL MD Record #: IMUGEN Account #: MERW Patient #: 2018013061 Antibody Capture Enzyme immunoassay Immunoblot igG (Western Blot) PLASMA #f 13061 TestDate: 09/17/2018 Valves reftact the relative ammount of B. burgdorler-specitic antibody comected for background. Normal Range: no antibody detected at <0.8 for IgM and <1 for igG and Iga. Comments: No IgM, IgG or IgA antibody to B. burgdorferi detected by capture EIA; the IgG immunoblot results fall within normal limits, Interpretation: No serologic evidence of infection with 8. burgdorferi (Lyme). Reective bands are Ested in kD of @. Ourgdorter’ antigens with which IgG ts reactive. Normal Range: Reactivity to <5 anfigens on each blot Mote 4: Recut MIE be weicales conjunction with cries preearinton sod ctner mackcel ans dlagrontis fnciage. Note 2: Anegeive rea dows not exude the passivity of infection wits Gore's turgaerten Aniinorties may Mon yal BS proneen a the Smne ef bond eamGlO cofection ar may Not yor be detaclaeie, Mote 3: the ontial LAA teat rent ts megarive (ie, mrnaci not ulated) and te galint's ceica Pskay shongly suggests election, te coteckon ofa Lecend earmpe is ongh reeemeres Note 4: Quantaive anitedy capture erzyens immunoassay values can Waly terol wittin 8 test mun Values chau net be conaiterme clinically memvaet outside of a comparative aneiysie gertoamed on the same Dadient cn ing same test cur. Mote 5: These tots were devtiopad and Deir perfomance chararterintcs determined by MUGEN. They have not been cidoed oF anproved by the FDA, The (aborslory ie regulated under CLIA wa quatiied to gartorm hagh-compaanity tasting. These tees are weed tor liniow pepowen. ‘They Wound Not Be vaganted 26 inven tipalicnal or tr resaeren, Mote &: A scaitwe west ray 1 oxchite he possibilty of & Succanstuly rested pest inbection. Mihse Platt M.D. Ph.D. Director The IMUGEN Wademark of Oxford immunctec, L . ©2017 Oxo immeuruien “Report Date: 09/17/2018 KEWIAL CLA rumber 2200050006 EFTA00299794